ACHIEVE LIFE SCIENCES, INC. - 8-K Filing
Achieve Life Sciences reported $10.5 million operating expenses and a $10.2 million net loss for Q1 2026 ended March 31, with cash balances of $29.3 million before the recent private placement expected to raise up to $354 million ($180 million upfront plus milestone-based warrants). The company appointed Andrew D. Goldberg as CEO and Christopher Martin as a board member while Thomas King will resign from his role on June 8, 2026. (Items: 2.02 Results of Operations and Financial Condition, 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 9.01 Financial Statements and Exhibits)
Tickers: $ACHV